Literature DB >> 17050877

Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance.

Casey L O'Connell1, William D Boswell, Vinay Duddalwar, Amy Caton, Lisa S Mark, Cheryl Vigen, Howard A Liebman.   

Abstract

PURPOSE: Advances in computed tomography (CT) scanning have led to the detection of unsuspected pulmonary emboli (PE) on routine cancer staging scans. We hypothesized that these patients had signs or symptoms suggestive of PE that may have been overlooked by their health care providers. PATIENTS AND METHODS: A retrospective chart review was performed on 59 patients found on routine cancer staging CT scans to have unsuspected PE. Information on patient demographics, malignancy characteristics, risk factors for venous thromboembolism (VTE), and symptoms was recorded. A retrospective case-control analysis was then performed using two age- and stage-matched control patients for each patient who had similar staging CT scans performed during the same period.
RESULTS: Fifty-two patients with unsuspected PE were identified. Forty-four percent had signs or symptoms commonly associated with PE; when fatigue was included, 75% were symptomatic. Ninety-two control patients were identified for 46 of the case patients. Patients with unsuspected PE were significantly more likely to have had a prior history of VTE (20% v 3%; P = .007). The patients with PE were significantly more likely than control patients to complain of fatigue (54% v 20%; P = .0002) and shortness of breath (22% v 8%; P = .02). There was no difference between the groups in administration of chemotherapy within 30 days, central venous catheter use, or erythropoietin therapy.
CONCLUSION: Seventy-five percent of patients found to have unsuspected PE on cancer staging CT scans were symptomatic. Fatigue and shortness of breath were significantly more common in patients with unsuspected PE than in control patients.

Entities:  

Mesh:

Year:  2006        PMID: 17050877     DOI: 10.1200/JCO.2006.06.5870

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Predicting and accounting for VTE in phase I cancer studies.

Authors:  A A Khorana
Journal:  Ann Oncol       Date:  2012-04-05       Impact factor: 32.976

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Cancer, clots and consensus: new understanding of an old problem.

Authors:  Gary H Lyman; Alok A Khorana
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

4.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

5.  Unsuspected pulmonary thromboemboli: a continuing clinical challenge.

Authors:  Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2013

Review 6.  Treating venous thromboembolism in patients with cancer.

Authors:  Caroline Piatek; Casey L O'Connell; Howard A Liebman
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

7.  Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C tool.

Authors:  Jeffrey A Kline; Pierre-Marie Roy; Martin P Than; Jackeline Hernandez; D Mark Courtney; Alan E Jones; Andrea Penaloza; Charles V Pollack
Journal:  Thromb Res       Date:  2012-04-03       Impact factor: 3.944

8.  Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations.

Authors:  M Carrier; A Lazo-Langner; S Shivakumar; V Tagalakis; P L Gross; N Blais; C A Butts; M Crowther
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

Review 9.  Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?

Authors:  A Maraveyas; M Johnson
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

Review 10.  Epidemiology of cancer-related venous thromboembolism.

Authors:  Ted Wun; Richard H White
Journal:  Best Pract Res Clin Haematol       Date:  2009-03       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.